Nephros, Inc.
Moat Score — Nephros, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Nephros's infection-control microfilters and dialysis ultrafilters are FDA 510(k)-cleared Class II medical devices, a real regulatory barrier that unregulated commercial filtration makers cannot sidestep, but the underlying filtration technology itself is not patent-protected in a way that keeps larger life-sciences players like Cytiva permanently out. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Nephros is a small, 36-employee company that outsources filter media manufacturing to a single supplier, Medica S.p.A.; it has no scale-driven cost advantage and is directly exposed to import tariffs on that relationship, which management says eroded margins in late 2025. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Flat gross margins of roughly 62% despite tariff headwinds suggest some ability to hold price in its FDA-cleared medical niche, but rising customer concentration (44% of 2025 revenue from the top three customers) limits how much pricing leverage Nephros can exert against its largest distributor relationships. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Water filtration hardware has no network effect; a hospital's adoption of Nephros filters does not make the product more valuable to other hospitals or users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Hospitals that qualify Nephros filters into their infection-control protocols face some switching friction from FDA-cleared product requalification and established replacement-cycle relationships, but Nephros itself acknowledges direct competition from Cytiva, Aquatools, and others at the point of initial sale, capping how durable this lock-in really is. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The medical point-of-use filtration niche is small enough that Nephros can be profitable at modest scale (~$18.8M revenue), but it is not large or specialized enough to deter much larger diversified filtration companies like 3M, Pentair, or Danaher's Cytiva from contesting it if they chose to invest more aggressively. |